Form 4: KORU Medical CEO's Routine Stock Activity

KORU Medical Systems CEO Linda M Tharby reported the vesting of restricted stock units and subsequent tax-related share disposition.

Summary

• Linda M Tharby, Chief Executive Officer and Director of KORU Medical Systems, Inc. (KRMD), reported transactions involving the company's common stock.
• On March 16, 2026, 15,968 shares of common stock were acquired by Tharby upon the vesting of restricted stock units, with an acquisition price of $0 per share.
• Concurrently, 5,756 shares of common stock were disposed of at a price of $4.28 per share to satisfy tax obligations related to the vesting of these restricted stock units.
• Following these transactions, Linda M Tharby directly beneficially owns 10,212 shares of KORU Medical Systems, Inc. common stock.
• The transactions were made pursuant to a contract, instruction, or written plan for the purchase or sale of equity securities of the issuer, intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as slightly positive due to the vesting of executive compensation, which aligns management's interests with shareholders, though the overall impact is largely neutral as it represents a routine compensation event.

Positives

• Vesting of 15,968 restricted stock units for Linda M Tharby, representing a form of compensation and alignment of executive interests with shareholder value.

Negatives

• Disposition of 5,756 shares of common stock at $4.28 per share to cover tax obligations, which reduces the direct beneficial ownership of the CEO, though this is a routine event for RSU vesting.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

StockSavvy.ai notes that Form 4 filings detailing executive stock transactions, particularly those involving the vesting of restricted stock units and subsequent tax withholding, are routine occurrences in the public markets. These transactions are a standard component of executive compensation packages and do not typically signal a change in company fundamentals or strategic direction.

Stakeholder Impact

• Shareholders: The transactions are routine and reflect executive compensation, which is a normal operational cost. The CEO's continued beneficial ownership of 10,212 shares maintains some alignment of interests.
• Employees: No direct impact on employees is indicated by this filing.

Key Dates

Recommendation

This Form 4 filing details routine insider transactions related to executive compensation (vesting of restricted stock units and subsequent tax withholding). It does not provide new information regarding the company's operational performance, financial health, or strategic outlook that would warrant a change in investment recommendation. The transactions were pre-planned under a Rule 10b5-1(c) plan, indicating they are not based on new material non-public information.

Keywords

KORU Medical Systems, KRMD, Linda M Tharby, Form 4, Insider Transaction, Restricted Stock Units, CEO Stock Activity, Equity Compensation, Rule 10b5-1